Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Aardvark Adventures -- Ignore unavailable to you. Want to Upgrade?

To: ~digs who wrote (1173)	7/10/2005 3:22:51 PM
From: ~digs	Read Replies (1) \| Respond to of 7944

OLGC 4.1 stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G OrthoLogic Corp., an orthobiologics drug-development company, engages in the development, testing, and commercialization of its Chrysalin product platform for treating traumatic and chronic orthopedic indications in both bone and soft tissue. All of these potential products are based on the Chrysalin synthetic peptide, also known as TP508, licensed from Chrysalis BioTechnology, Inc. TP508 is a 23-amino acid synthetic peptide representing a receptor-binding domain of the human thrombin molecule, a naturally occurring molecule in the body responsible for both blood clotting, as well as for initiating various of the cellular events responsible for tissue repair in bone and cartilage. As of March 31, 2004, the company enrolled patients in a phase III Chrysalin product human clinical trial for fracture indications, completed the enrollment of patients in a Phase I/II spine fusion clinical trial, had one potential product in late-stage preclinical development, and was planning the development for two additional areas of research.